Average Price Target: $9.50
▲ +156.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Medicenna Therapeutics in the last 3 months. The average price target is $9.50, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 156.06% upside from the last price of $3.71.
The current consensus among 4 polled investment analysts is to buy stock in Medicenna Therapeutics.
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.